Holen Sie sich die Stockscreener-App
6.77
83.74%
-34.83
Schlusskurs vom Vortag:
$41.60
Offen:
$6.2
24-Stunden-Volumen:
4.92M
Relative Volume:
44.41
Marktkapitalisierung:
$63.67M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-83.16%
1M Leistung:
-80.03%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$5.65
$7.01
1-Wochen-Bereich:
$5.65
$43.65
52-Wochen-Spanne:
$5.65
$43.65
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
Firmenname
Tvardi Therapeutics Inc
Sektor
Branche
Telefon
(713) 489-8654
Adresse
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Vergleichen Sie TVRD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
6.79 | 390.10M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.84 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
471.96 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
551.80 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
808.25 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.09 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-14 | Eingeleitet | Raymond James | Outperform |
| 2025-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-12 | Eingeleitet | Piper Sandler | Overweight |
| 2025-05-21 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-15 | Eingeleitet | BTIG Research | Buy |
| 2024-06-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | Herabstufung | Needham | Buy → Hold |
| 2024-06-13 | Herabstufung | Stifel | Buy → Hold |
| 2023-03-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-11-01 | Fortgesetzt | Canaccord Genuity | Buy |
| 2021-08-03 | Eingeleitet | JP Morgan | Neutral |
| 2020-04-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-29 | Bestätigt | Laidlaw | Buy |
| 2019-02-06 | Fortgesetzt | Jefferies | Buy |
| 2019-01-15 | Eingeleitet | BofA/Merrill | Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Eingeleitet | Jefferies | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2018-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2018-02-12 | Hochstufung | Janney | Neutral → Buy |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
Alle ansehen
Tvardi Therapeutics Inc Aktie (TVRD) Neueste Nachrichten
Live market analysis of Tvardi Therapeutics Inc.2025 Risk Factors & Real-Time Stock Entry Alerts - newser.com
Why Did Tvardi Therapeutics Stock Plummet 87% Pre-Market Today? - Asianet Newsable
Why Is Tvardi Therapeutics Stock (TVRD) Down 85% Today? - TipRanks
Does Tvardi Therapeutics Inc. stock trade at a discount to peersJuly 2025 Reactions & Safe Capital Growth Tips - newser.com
Tvardi Therapeutics' Potential Lung Disease Treatment Fails to Meet Goals; Shares Decline Pre-Bell - MarketScreener
Published on: 2025-10-13 07:20:38 - newser.com
Using RSI to spot recovery in Tvardi Therapeutics Inc.2025 Valuation Update & Reliable Momentum Entry Alerts - newser.com
Will Tvardi Therapeutics Inc. benefit from macro trendsJuly 2025 Update & Breakout Confirmation Trade Signals - newser.com
Using AI based signals to follow Tvardi Therapeutics Inc.2025 Year in Review & Real-Time Stock Entry Alerts - newser.com
Tvardi Therapeutics stock plunges after failed IPF trial data - Investing.com
Barclays initiates coverage on Tvardi Therapeutics stock with Overweight rating - Investing.com
Can swing trading help recover from Tvardi Therapeutics Inc. losses2025 Market Overview & AI Enhanced Execution Alerts - newser.com
Using data models to predict Tvardi Therapeutics Inc. stock movement2025 Earnings Surprises & Community Consensus Trade Alerts - newser.com
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) most popular amongst retail investors who own 57% of the shares, institutions hold 26% - Yahoo Finance
Tvardi Therapeutics Inc. stock volume spike explainedJuly 2025 Pullbacks & Weekly Market Pulse Updates - newser.com
Published on: 2025-10-10 08:50:26 - newser.com
Best data tools to analyze Tvardi Therapeutics Inc. stockJuly 2025 Analyst Calls & High Accuracy Swing Entry Alerts - newser.com
Tvardi Therapeutics Inc. stock daily chart insightsJuly 2025 Pullbacks & Weekly Top Gainers Alerts - newser.com
Is Tvardi Therapeutics Inc 69C a good long term investmentStock Rotation Strategies & Get Tomorrow’s Winners Today With AI - earlytimes.in
Published on: 2025-10-06 07:23:43 - newser.com
Order flow analysis tools used on Tvardi Therapeutics Inc.July 2025 Short Interest & Weekly Stock Performance Updates - newser.com
Is it time to cut losses on Tvardi Therapeutics Inc.Trade Exit Summary & Entry Point Confirmation Alerts - newser.com
Will Tvardi Therapeutics Inc. (69C) stock beat value stocks2025 Market Trends & Weekly Watchlist for Hot Stocks - newser.com
Why analysts remain bullish on Tvardi Therapeutics Inc. stockAnalyst Downgrade & Risk Controlled Daily Plans - newser.com
Will Tvardi Therapeutics Inc. price bounce be sustainableBull Run & Entry Point Confirmation Alerts - newser.com
Is Tvardi Therapeutics Inc. stock cheap at current valuationJuly 2025 Trends & Weekly Setup with ROI Potential - newser.com
What dividend safety score for Tvardi Therapeutics Inc. stockEntry Point & Verified Momentum Watchlists - newser.com
What the charts say about Tvardi Therapeutics Inc. today2025 Volume Leaders & Intraday High Probability Setup Alerts - newser.com
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Published on: 2025-09-30 05:12:21 - newser.com
Published on: 2025-09-30 03:36:47 - newser.com
Finanzdaten der Tvardi Therapeutics Inc-Aktie (TVRD)
Es liegen keine Finanzdaten für Tvardi Therapeutics Inc (TVRD) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Tvardi Therapeutics Inc-Aktie (TVRD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Terrillion Scott | SEC'Y; CHIEF COMPLIANCE & G.C. |
Feb 28 '25 |
Sale |
4.76 |
163 |
776 |
7,190 |
| Posner Christopher | PRESIDENT AND CEO |
Feb 04 '25 |
Sale |
4.72 |
372 |
1,756 |
13,692 |
| Posner Christopher | PRESIDENT AND CEO |
Nov 04 '24 |
Sale |
0.29 |
3,668 |
1,064 |
168,768 |
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):